They also found that the higher blood activity of both agents presented a slower blood clearance and a lower tumor-to-blood ratios (ALCAM-3Lamide-DOTA-cDb: 1.4, ALCAM-3 L-thioether-DOTA-cDb: 1.9) compared to previous agent (64Cu-DOTA-CysDb). Here, ALCAM is linked to neoplasm.